Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression in patients treated with ivacaftor in a real-world setting for up to 5  years.

Source: Journal of Cystic Fibrosis - June 9, 2019 Category: Respiratory Medicine Authors: Nataliya Volkova, Kristin Moy, Jennifer Evans, Daniel Campbell, Simon Tian, Christopher Simard, Mark Higgins, Michael W. Konstan, Gregory S. Sawicki, Alexander Elbert, Susan C. Charman, Bruce C. Marshall, Diana Bilton Source Type: research